Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current controversies in the management of early breast cancer.
Estévez LG, Martín M, Alba E, Colomer R, Lobo F, Lluch A, Adrover E, Albanell J, Barnadas A, García-Mata J, Llombart A, Muñoz M, Rodríguez C, Sánchez-Rovira P, Seguí MA, Tusquets I. Estévez LG, et al. Among authors: adrover e. Clin Transl Oncol. 2007 Jun;9(6):375-84. doi: 10.1007/s12094-007-0070-z. Clin Transl Oncol. 2007. PMID: 17594952 Review.
Current controversies in the management of breast cancer.
Tusquets I, García-Estévez L, Adrover E, Calvo L, Alvarez I, García Mata J, Fernández Y, Margueli M, Seguí MA, Muñoz M, Rodríguez C, Rodríguez Lescure A, Colomer R, Gascón P, Martín M, Alba E, Barnadas A, Llombart A, Albanell J, Lluch A. Tusquets I, et al. Among authors: adrover e. Clin Transl Oncol. 2010 Apr;12(4):278-86. doi: 10.1007/s12094-010-0504-x. Clin Transl Oncol. 2010. PMID: 20462837 Review.
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR. Martín M, et al. Among authors: adrover e. Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766587 Free article. Clinical Trial.
Advanced breast cancer: chemotherapy phase III trials that change a standard.
Estevez LG, Tusquets I, Muñoz M, Adrover E, Rovira PS, Seguí MA, Rodríguez CA, Lescure AR, Ruiz M, Alvarez I, Mata JG. Estevez LG, et al. Among authors: adrover e. Anticancer Drugs. 2007 Aug;18(7):843-59. doi: 10.1097/CAD.0b013e3280bad81a. Anticancer Drugs. 2007. PMID: 17581310
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G. Gallardo A, et al. Among authors: adrover e. Br J Cancer. 2012 Apr 10;106(8):1367-73. doi: 10.1038/bjc.2012.85. Epub 2012 Mar 27. Br J Cancer. 2012. PMID: 22454081 Free PMC article.
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.
Márquez-Rodas I, Pollán M, Escudero MJ, Ruiz A, Martín M, Santaballa A, Martínez Del Prado P, Batista N, Andrés R, Antón A, Llombart A, Fernandez Aramburu A, Adrover E, González S, Seguí MA, Calvo L, Lizón J, Rodríguez Lescure Á, Ramón Y Cajal T, Llort G, Jara C, Carrasco E, López-Tarruella S. Márquez-Rodas I, et al. Among authors: adrover e. PLoS One. 2017 Oct 6;12(10):e0184181. doi: 10.1371/journal.pone.0184181. eCollection 2017. PLoS One. 2017. PMID: 28985233 Free PMC article.
60 results